BioVaxys Technology Corp. CEO James Passin tells Proactive its France-based bioproduction partner, BioElpida, has completed the creation of multiple OVCAR-3 cell banks as the next step in the Good Manufacturing Practice (GMP) process development for the company's BVX-0918 vaccine aimed at treating platinum-resistant ovarian cancer.
The Vancouver-based biotechnology company noted that the OVCAR-3 cell line is mandatory for creating the identity assays that will have to be performed on every batch of ovarian cancer vaccines. The assay is required by regulatory bodies in the European Union and the US.
